Hemifacial Spasm Market : A Comprehensive Overview of the Current Trends

Comments · 844 Views

Hemifacial spasm is a painless neurological disorder consisting of persistent or fleeting involuntary contractions or twitches of the muscles innervated by the touching of a blood vessel to a facial nerve, or due to a facial nerve injury, or in severe cases, a tumor.

Market overview

According to a report published by Market Research Future (MRFR), the global hemifacial spasm market share is projected to reach USD 3170 million by 2030 at a CAGR of 5.4% over the forecast period of 2022 to 2030.

Hemifacial spasm is a painless neurological disorder consisting of persistent or fleeting involuntary contractions or twitches of the muscles innervated by the touching of a blood vessel to a facial nerve, or due to a facial nerve injury, or in severe cases, a tumor.

The influential factors driving the growth of the global hemifacial spasm market is the improvement of the healthcare sector globally, owing to the developing economic conditions, government efforts such as favorable regulations and expenditure towards research and development for providing better healthcare facilities, and the growing awareness among consumers regarding healthcare.

Additionally, technological advancements in medical science have risen the chances of treatment for almost all disorders.

On the other hand, challenges faced by the global hemifacial spasm market are the cost of treatment, side effects of the botulinum toxin which is used during treatment, and the presence of counterfeit drugs or treatment methods.

Key Players

global hemifacial spasm market players are US WorldMeds (U.S.), Abbott (U.S.), Cephalon Inc. (U.S.), Shire plc (U.S.), Stryker (U.S.), Sunovion Pharmaceuticals, Inc. (U.S.), Pfizer (U.S.), Revance Therapeutics, Inc. (U.S.), Johnson Johnson Services, Inc. (U.S.), Valeant Pharmaceuticals International, Inc., (Canada), GlaxoSmithKline plc (UK), Merz Pharma GmbH and Co. KGaA (Germany), Sanofi S.A (France), UCB S.A. (Belgium), Ipsen Group (France), Novartis AG (Switzerland), Allergan, Inc. (Ireland), Roche (Switzerland), Medytox,Inc. (South Korea), and LLC. (UAE).

Segmental Analysis

The global hemifacial spasm market outlook is segmented on the basis of diagnosis, treatment, end user, and region.

Based on the diagnosis, the market has been segmented into magnetic resonance imaging (MRI), angiography (arteriography), computed tomography (CT or CAT scan), and others.

Based on treatment, the hemifacial spasm market insights has been segmented into medical treatment, surgical treatment, physical therapy, combinational therapy, transcutaneous electric nerve stimulation (TENS) therapy, and others. The medical treatment segment has been sub-segmented into Botulinum Neurotoxin (BoNT) injections, and pharmaceuticals.  The surgical treatment is sub-segmented into microvascular decompression (MVD), and others.

Based on end-users, the market for hemifacial spasm has been segmented into hospitals, clinics, diagnostic centers, drug stores, pharmacies, and others.

Based on regions, the market has been segmented into the Americas, Europe, Asia Pacific, and the Middle East And Africa.

Regional Analysis

The Americas are the largest regional market for hemifacial spasms and are assessed to account for the leading market share over the forecast period. North America is the hub for technological advancements, and the governments provide favorable regulations and expenditure towards the development of the healthcare sector, consequently driving the growth of the hemifacial spasm market in the region.

Europe has the second highest market share and is estimated to be a lucrative region over the forecast period for the hemifacial spasm market due to the investments made by the governments towards research and development for healthcare and improving reimbursement policies, and the presence of significant market players.

The Asia Pacific has been accounted for the fastest growing region in the global hemifacial spasm market and has been estimated to witness substantial growth over the forecast period, owing to the rise in the patient population, and the development of healthcare sector across emerging economies such as China, India and Japan.

The middle east and Africa is an emerging region in the global hemifacial spasm market and is expected to showcase slow, gradual growth over the forecast period.

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research Consulting Services.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York,

New York 10013

United States of America

Comments